3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDIV
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
3
Tumor-Agnostic
1
Thoracic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
86
Lung Neoplasms
32
Small Cell Lung Carcinoma
18
Melanoma
17
Mesothelioma
13
Neoplasms
11
Colorectal Neoplasms
9
Carcinoma, Renal Cell
9
Squamous Cell Carcinoma of Head and Neck
7
Neoplasm Metastasis
7
Mesothelioma, Malignant
7
Carcinoma, Transitional Cell
7
Ovarian Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Liver Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Kidney Neoplasms
4
Brain Neoplasms
4
Carcinoma, Merkel Cell
3
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Interventions
Carboplatin
12
Pemetrexed
11
pembrolizumab
10
Paclitaxel
6
Cisplatin
6
Erlotinib Hydrochloride
5
Docetaxel
5
Nivolumab
4
Gefitinib
4
spartalizumab
3
osimertinib
3
Gemcitabine
3
EC145
3
Crizotinib
3
Afatinib
3
technetium 99m etarfolatide
2
pralsetinib
2
fludarabine
2
cemiplimab
2
brigatinib
2
alpha-2'-deoxythioguanosine
2
aldesleukin
2
Vinorelbine
2
Radiotherapy
2
Quality of Life
2
MORAb-202
2
Immunotherapy
2
Drug Therapy
2
Cyclophosphamide
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Ipilimumab
×
Thoracic
×
Clear all
NCT03695835
2020-07-22
NIRPA
Gary Onik MD
Completed
27 enrolled